DOCSLIB.ORG

Coronavirus: Quello Che C'è Da Sapere – 28 Maggio 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Coronavirus: Quello Che C'è Da Sapere – 28 Maggio 2021 Coronavirus: quello che c’è da sapere – 28 maggio 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Il virus può mutare? ..................................................................................5 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................45 I bambini sono più soggetti all’infezione? .............................................13 Quali sono i rischi sanitari legati all’epidemia? .....................................56 La malattia può essere trasmessa da una persona senza sintomi? .....15 Quali sono i rischi politici, economici e sociali legati all’epidemia? ....60 L’infezione può essere trasmessa dagli animali all’uomo (e Quali sono le nazioni più colpite dall’epidemia? ....................................62 viceversa)? ...............................................................................................17 Quanto è diffusa l’epidemia in Italia? .....................................................63 Come è possibile limitare la diffusione del virus? .................................19 È utile indossare la mascherina? ............................................................19 Quali misure sono state prese in Italia? .................................................66 Quanto dura l’immunità? È possibile reinfettarsi? ................................20 Possiamo viaggiare in Italia ed all’estero? ............................................71 Il virus può diventare endemico?............................................................22 Dove è possibile trovare informazioni affidabili? ..................................74 I prodotti alimentari che acquistiamo e l’acqua potabile sono sicuri? .22 Il Servizio Sanitario Nazionale e il ruolo dell’Istituto Nazionale Cosa fare se si sospetta di aver contratto l’infezione? ..........................23 Malattie Infettive “Lazzaro Spallanzani” ................................................75 Indice dei grafici e delle tabelle Incidenza del Covid-19 negli ultimi 14 giorni, casi per 100.000 Andamento delle vaccinazioni nel mondo, 28 maggio 2021..................37 abitanti, settimane 19-20 (10 - 23 maggio) ..............................................1 Andamento della campagna vaccinale in Italia, 28 maggio 2021 .........38 Totale casi e decessi nel mondo, 28 maggio 2021 ...................................3 Andamento della campagna vaccinale per regione, 28 maggio 2021 ...39 I quattro scenari possibili di inizio dell’epidemia ....................................4 Prime 10 nazioni per numero di nuovi casi, 28 maggio 2021 ................43 Riepilogo delle principali varianti virali ....................................................6 L’epidemia in Italia, 28 maggio 2021 ......................................................44 Incidenza del Covid-19 in Europa, casi per 100.000 abitanti, Sperimentazioni cliniche approvate in Italia al 29 aprile 2020 .............46 settimane 19-20 (10 - 23 maggio) ............................................................8 Nuovi casi positivi in Italia nell’ultimo mese ..........................................53 Incremento giornaliero dei casi positivi nel mondo nell’ultimo mese ..11 Le dieci Regioni italiane con più casi, 28 maggio 2021 .........................54 Strumenti di mitigazione per ridurre la trasmissione del virus .............12 Decessi Covid-19 per 100.000 abitanti in Italia, 28 maggio 2021 .........57 Decessi Covid-19 per milione di abitanti, 28 maggio 2021 ...................14 Tasso di positività dei tamponi effettuati in Italia ..................................58 Distribuzione dei casi nel mondo e in Europa, 28 maggio 2021 ............16 Trend settimanale e mensile di casi e decessi nelle regioni OMS, 28 Le dieci nazioni con più casi e decessi, 28 maggio 2021 ......................18 maggio 2021 ............................................................................................62 Casi positivi per fasce di età in Italia 27 aprile - 27 maggio .................25 Indicatori dell’epidemia per regione, 28 maggio 2021 ..........................64 Principali patologie associate ai decessi in Italia, 29 aprile 2021.........26 Fase 2: monitoraggio regionale 3 - 9 maggio 2021 ................................65 Mortalità in eccesso in Italia tra il 1 gennaio 2020 e il 28 febbraio Decessi per fasce di età in Italia, 19 maggio 2021 ................................28 2021 rispetto alla media 2015-2019 .......................................................67 Casi e decessi giornalieri nelle aree più colpite, 28 maggio 2021 ........30 Decessi in Italia 1 marzo 2020 - 28 febbraio 2021 a confronto con la Vaccini approvati per l’utilizzo e sperimentazioni interrotte, 28 media 2015-2019 .....................................................................................68 maggio 2021 ............................................................................................32 Andamento dei decessi in Italia suddivisi per regione, gennaio 2020 Candidati vaccini in fase clinica, 28 maggio 2021 .................................33 - febbraio 2021 ........................................................................................73 Per agevolare la lettura, nell’indice e nel documento sono evidenziate in giallo le parti aggiornate rispetto all’edizione precedente. https://www.inmi.it/aggiornamenti-coronavirus Incidenza del Covid-19 negli ultimi 14 giorni, casi per 100.000 abitanti, settimane 19-20 (10 - 23 maggio) Fonte: ECDC a cura di Salvatore Curiale - direzione scientifica Istituto Nazionale Malattie infettive “Lazzaro Spallanzani” IRCCS – Roma – © INMI 2021 1 Quando è iniziata l’epidemia? ha condotto una analisi retrospettiva6 sui tamponi oro-faringei dei Il 31 dicembre 2019 le autorità sanitarie cinesi hanno reso nota la casi sospetti di morbillo raccolti tra settembre 2019 e febbraio 2020 presenza di un focolaio di sindrome febbrile, associata a polmoni- nell’ambito della rete di sorveglianza integrata morbillo e rosolia Mo- te di origine sconosciuta, tra gli abitanti di Wuhan, città di circa 11 RoNet. Dall’analisi è emersa la positività ad un gene del SARS-CoV-2 milioni di abitanti situata nella provincia di Hubei, nella Cina Cen- del campione di un bambino di 4 anni abitante nell’hinterland mila- tro-meridionale, alla confluenza tra il Fiume Azzurro e il fiume Han, nese e senza alcun link con la Cina, che il 21 novembre 2019 aveva a circa 1.100 chilometri da Pechino, 800 da Shangai, 1.000 da Hong manifestato sintomi (tosse e rinite), il 30 novembre era stato portato Kong. In un primo momento il punto di partenza dell’infezione è al pronto soccorso con sintomi respiratori e vomito, il 1° dicembre stato identificato nel mercato del pesce e di altri animali vivi (c.d. aveva avuto un’eruzione cutanea simile a quella che si manifesta con “wet market”) di Huanan, al centro della città di Wuhan, che è sta- il morbillo, e il 5 dicembre aveva effettuato il tampone oro-faringeo to chiuso il 1 gennaio 2020, ma è ormai confermato che il mercato è per la diagnosi clinica del sospetto morbillo. Un altro studio condotto stato soltanto il primo amplificatore dell’infezione, iniziata settima- dall’Istituto Tumori di Milano e dall’Università di Siena7 ha cercato ne prima. gli anticorpi del SARS-CoV-2 nei campioni di sangue prelevati a 959 L’analisi del sangue di oltre 38.000 donatori sani a Wuhan e in altre pazienti che tra settembre 2019 e marzo 2020 si erano sottoposti a due città cinesi, Shenzen (estremo sud) e Shijiazhuang (estremo nord) screening per la prevenzione del cancro al polmone. Gli anticorpi del tra gennaio ed aprile 2020) ha evidenziato una prevalenza, ovvero coronavirus sono stati individuati nell’11,6% dei pazienti, in alcuni una percentuale di persone che avevano sviluppato anticorpi contro casi in campioni prelevati a settembre del 2019. La ricerca sembre- il virus SARS-CoV-2, del 2,66% a Wuhan, dello 0,033% a Shenzen rebbe indicare una circolazione molto precoce del SARS-CoV-2 tra e dello 0,0028% a Shijiazhuang1. individui asintomatici in Italia diversi mesi prima dell’identificazione Nel corso di una conferenza stampa svoltasi a Wuhan il 9 febbra- del primo paziente. Si tratta di una ipotesi che necessita di ulteriori io 2021 con gli esperti dell’Organizzazione Mondiale della Sanità e solide conferme, da effettuarsi con metodi adeguatamente validati. (OMS) chiamati ad indagare sull’origine
Load more

Recommended publications
  • Nature.2021.06.12 [Sat, 12 Jun 2021]
    [Sat, 12 Jun 2021] This Week News in Focus Books & Arts Opinion Work Research | Next section | Main menu | Donation | Next section | Main menu | | Next section | Main menu | Previous section | This Week Embrace the WHO’s new naming system for coronavirus variants [09 June 2021] Editorial • The World Health Organization’s system should have come earlier. Now, media and policymakers need to get behind it. Google’s AI approach to microchips is welcome — but needs care [09 June 2021] Editorial • Artificial intelligence can help the electronics industry to speed up chip design. But the gains must be shared equitably. The replication crisis won’t be solved with broad brushstrokes [08 June 2021] World View • A cookie-cutter strategy to reform science will cause resentment, not improvement. A light touch changes the strength of a single atomic bond [07 June 2021] Research Highlight • A technique that uses an electric field to tighten the bond between two atoms can allow a game of atomic pick-up-sticks. How fit can you get? These blood proteins hold a clue [04 June 2021] Research Highlight • Scientists pinpoint almost 150 biomarkers linked to intrinsic cardiovascular fitness, and 100 linked to fitness gained from training. Complex, lab-made ‘cells’ react to change like the real thing [02 June 2021] Research Highlight • Synthetic structures that grow artificial ‘organelles’ could provide insights into the operation of living cells. Elephants’ trunks are mighty suction machines [01 June 2021] Research Highlight • The pachyderms can nab a treat lying nearly 5 centimetres away through sheer sucking power. More than one-third of heat deaths blamed on climate change [04 June 2021] Research Highlight • Warming resulting from human activities accounts for a high percentage of heat-related deaths, especially in southern Asia and South America.
    [Show full text]
  • June 11, 2021 the Honorable Xavier Becerra Secretary Department of Health and Human Services 200 Independence Ave S.W. Washingto
    June 11, 2021 The Honorable Xavier Becerra Secretary Department of Health and Human Services 200 Independence Ave S.W. Washington, D.C. 20201 The Honorable Francis Collins, M.D., Ph.D. Director National Institutes of Health 9000 Rockville Pike Rockville, MD 20892 Dear Secretary Becerra and Director Collins, Pursuant to 5 U.S.C. § 2954 we, as members of the United States Senate Committee on Homeland Security and Governmental Affairs, write to request documents regarding the National Institutes of Health’s (NIH) handling of the COVID-19 pandemic. The recent release of approximately 4,000 pages of NIH email communications and other documents from early 2020 has raised serious questions about NIH’s handling of COVID-19. Between June 1and June 4, 2021, the news media and public interest groups released approximately 4,000 pages of NIH emails and other documents these organizations received pursuant to Freedom of Information Act requests.1 These documents, though heavily redacted, have shed new light on NIH’s awareness of the virus’ origins in the early stages of the COVID- 19 pandemic. In a January 9, 2020 email, Dr. David Morens, Senior Scientific Advisor to Dr. Fauci, emailed Dr. Peter Daszak, President of EcoHealth Alliance, asking for “any inside info on this new coronavirus that isn’t yet in the public domain[.]”2 In a January 27, 2020 reply, Dr. Daszak emailed Dr. Morens, with the subject line: “Wuhan novel coronavirus – NIAID’s role in bat-origin Covs” and stated: 1 See Damian Paletta and Yasmeen Abutaleb, Anthony Fauci’s pandemic emails:
    [Show full text]
  • Melissaossmanpro.Pdf
    August 19, 2021 Chairman Lipps, Vice Chair Holmes, Ranking Member Russo, and Members of the House Health Committee, thank you for the opportunity to provide proponent testimony on House Bill 248. My family and I are asking that Ohio HB248 be passed in order to protect the individual freedoms we currently have as American citizens. I work in a corporate setting and my husband owns a small business. We have two young daughters who are relying on us to provide for them and protect their rights. I support this bill in hopes that they can grow up with the same liberties we have had. Segregation and discrimination over individual health choices should be taken seriously and passing this bill is key to avoiding those types of issues in the future. I am not a scientist, but I am a mom, a wife, and a daughter who takes the health of my family very seriously. I have done extensive amounts of research on the SARS-COV2 virus and subsequent vaccines. There are also many health experts that provide me with helpful information. I am sure you are receiving many testimonies about the large numbers of vaccine injuries and even deaths that have occurred during this vaccine campaign. Personally, I know two women who have had severe menstrual issues (requiring surgery) that they can connect back to occurring right after the vaccine. My friends’ cousin passed away at only 23 years old from an enlarged heart after receiving the vaccine. The stories go on and on. The point is that no legislation should force my family and I to inject ourselves with substances that have side effects such as this.
    [Show full text]
  • The Highly Pathogenic Avian Influenza A(H5N1) Virus: a Twenty-Year Journey of Narratives and (In)Secure Landscapes
    The Highly Pathogenic Avian Influenza A(H5N1) Virus: a twenty-year journey of narratives and (in)secure landscapes Philip Rolly Egert Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Science, Technology, and Society Barbara L. Allen (Chair) Daniel Breslau Bernice L. Hausman David C. Tomblin March 18, 2016 Falls Church, Virginia Keywords: H5N1, HPAI, highly pathogenic avian influenza virus, pandemic, social justice, bioterrorism, bioethics, biopower, tacit knowledge, dual-use dilemma, dual-use research of concern, emerging infectious disease Copyright Philip R. Egert The Highly Pathogenic Avian Influenza A(H5N1) Virus: a twenty-year journey of narratives and (in)secure landscapes Philip Rolly Egert ABSTRACT This dissertation is comprised of two manuscripts that explore various contestations and representations of knowledge about the highly pathogenic avian influenza H5N1virus. In the first manuscript, I explore three narratives that have been produced to describe the 20-year journey of the virus. The journey begins in 1996 when the virus was a singular localized animal virus but then over the next 20 years multiplied its ontological status through a (de)stabilized global network of science and politics that promoted both fears of contagion and politics of otherness. Written by and for powerful actors and institutions in the global North, the narratives focused on technical solutions and outbreak fears. In doing so, the narratives produced policies and practices of biopower that obscured alternative considerations for equity, social justice, and wellbeing for the marginalized groups most directly affected by the H5N1 virus.
    [Show full text]
  • Honouring the Peasants Day 2 MARCH 2021 2 NATIONAL the GLOBAL NEW LIGHT of MYANMAR
    WEATHER-BASED INSURANCE KEY TO EASING IMPACT OF CLIMATE CHANGE ON FARMERS PAGE-8 (OPINION) Vol. VII, No. 320, 4th Waning of Tabodwe 1382 ME www.gnlm.com.mm Tuesday, 2 March 2021 State Administration Council Chairman Senior General Min Aung Hlaing sends Message of Greetings on Peasants Day Esteemed peasants, Esteemed peasants, Today is a historic day, which honours the peasants all over the country. Peas- The Ministry of Agriculture, Livestock and Irrigation (MOALI) is cooperating ants, I wish you all health and happiness and auspiciousness on this significant with the relevant ministries in distributing advanced technology for the availa- day and also pray for success in your agricultural undertakings. bility of quality strains, water, anti-pest measures, and smooth transport for the Agricultural products not only serve as the backbone of the food industry but agricultural products to reach local and foreign markets in order to produce also as the main source of income for millions of rural people. As agriculture is crops, meat and fish of high quality. shaping the development models of the economy, social affairs and environment, The MOALI is the main body for the development of the agriculture sector, its growth has been realized as the main task of the State. and apart from distributing pedigree strains and technology to enable farmers Peasants are the food-providers and benefactors of the country as their hard to raise or cultivate or produce quality crops and farm animals, it is also helping work helps ensure daily food supplies for the people, generate employment oppor- farmers to apply good agricultural practices (GAP), good animal husbandry tunities and earn foreign exchange income from export.
    [Show full text]
  • Medical JOUR
    RHODE ISLAND M EDiCAL J ournal ZOOM – It’s a Match! Virtual National Match Day is largest on record See page 75 R SPECIAL SECTION, PART II BIOMEDICAL/TRANSLATIONAL RESEARCH in RI GUEST EDITORS: JAMES PADBURY, MD; BONGSUP CHO, PhD ApRiL 2021 VOLUME 104 • NUMBER 3 iSSN 2327-2228 REINVENTING WHAT YOU EXPECT FROM A MEDICAL PROFESSIONAL LIABILITY PROVIDER. With Coverys, you can reduce the distractions that come between diagnosis and outcomes. By leveraging claims data and analytics plus innovative educational resources, we’re helping doctors and administrators reduce distractions and focus on improving clinical, operational, and financial outcomes.Visit coverys.com Insurance products issued by ProSelect® Insurance Company (NE, NAIC 10638) and Preferred Professional Insurance Company® (NE, NAIC 36234). RHODE ISLAND M EDICAL J OURNAL 15 Translational Research: The Time is Now JAMES F. PADBURY, MD BONGSUP P. CHO, PhD GUEST EDITORS James F. Padbury, MD Bongsup Cho, PhD 17 The Time is NOW: Filling the Gaps in Treatment of Opioid-Exposed Infants: A Prospective, Pragmatic, Randomized Control Drug Trial ADAM J. CZYNSKI, DO; ABBOT R. LAPTOOK, MD 22 COBRE on Opioid and Overdose: A Collaborative Research-Based Center Addressing the Crises in Rhode Island and Beyond TRACI C. GREEN, PhD, MSc; ELIANA KAPLOWITZ, BA; KIRSTEN LANGDON, PhD; JACLYN M.W. HUGHTO, PhD, MPH; WILLIAM C. GOEDEL, PhD; ADAM J. CZYNSKI, DO; GAYLE FRASER, BS; JOSIAH RICH, MD, MPH 27 Brown University COBRE Center for Addiction and Disease Risk Exacerbation PETER M. MONTI, PhD; JENNIFER W. TIDEY, PhD; JASJIT S. AHLUWALIA, MD 32 The Center of Biomedical Research Excellence (COBRE) for Perinatal Biology – Accomplishments, Impact, and Long-term Results SUNIL K.
    [Show full text]
  • Covid-19: South Africa Pauses Use of Oxford Vaccine After
    NEWS BMJ: first published as 10.1136/bmj.n372 on 8 February 2021. Downloaded from The BMJ Cite this as: BMJ 2021;372:n372 Covid-19: South Africa pauses use of Oxford vaccine after study casts http://dx.doi.org/10.1136/bmj.n372 doubt on efficacy against variant Published: 08 February 2021 Elisabeth Mahase Rollout of the Oxford-AstraZeneca covid-19 vaccine is going to be hard to estimate. Without seeing results in South Africa has been paused after a study in 2000 in detail it isn’t possible to be sure how firm these healthy and young volunteers reported that it did not conclusions are. protect against mild and moderate disease caused by “However, if the press reports are correct it does seem the new variant (501Y.V2) that emerged there. of concern that protection against disease was not The study, which has not been published and was shown. The findings of the Novavax vaccine trial of seen by the Financial Times,1 looked at the efficacy 60% efficacy in the prevention of disease of any of the vaccine against the 501Y.V2 variant—which severity in HIV negative volunteers in South Africa accounts for around 90% of cases in South Africa—in might also suggest that vaccines will need to be HIV negative people. While reports suggested that updated in line with emerging mutations of the the vaccine was ineffective at preventing mild to virus.” moderate disease in that population, no data have 1 Mancini DP, Kuchler H, Pilling D, Cookson C, Cotterill J. Oxford/AstraZeneca been made available to the public.
    [Show full text]
  • Peter Daszak IPBES Scoping for the Nexus Assessment: Health
    IPBES Scoping for the Nexus Assessment: Health & Linkages Peter Daszak [email protected] The focus for this session Three thematic areas: 1. Biodiversity & health 2. Global environmental change & health 3. Food, water & health Your suggestions on: • Scope of the assessment • Questions to address Post-2020 Biodiversity Framework and Global Goals . Aichi Biodiversity Targets, particularly: • Target 14. Biodiversity and Ecosystem Services . Sustainable Development Goals, e.g.: • 3. Health; • 6. Clean Water and Sanitation; • 13. Climate Action; • 14. Aquatic Ecosystems; • 15. Terrestrial Ecosystems; • 17. Partnerships . Global Health Security Agenda (Prevent, Detect, Respond) . Sendai Framework for Disaster Risk Reduction 2015-2030 • Bangkok Principles for implementation of health aspects One Health approach • Health of people, wildlife, livestock, environment • Impact of human-mediated global environmental change on health across all sectors Biodiversity’s Health Services Pharmaceuticals • Penicillin (fungus); Digitalis (foxglove plant); Quinine and quinidine (Peruvian Cinchona tree); Morphine and codeine (poppies); Taxol (Pacific Yew tree) Welfare • Link between good mental health and open spaces, biodiversity, forests/parks • Outdoor activity linked to overall fitness and lack of disease • Dietary diversity and nutritional health Protection against disease • Lower risk emerging diseases from undisturbed intact forest Honey Bee Declines in U.S.A. Biodiversity loss & health Intact Forest Residential Urban Culex mosquitoes prefer
    [Show full text]
  • Novavax Covid Vaccine Protects People Against
    University of Witwatersrand in Johannesburg. The 501Y.V2 lineage spread so rapidly that it caused nearly all of the COVID-19 cases that the trial recorded. In the group of people who received two vaccine doses, 15 developed COVID-19, compared with 29 of the participants who received a placebo injection. This equates to an efficacy of 49.4%. The study enrolled 240 people who are HIV-positive, and when Madhi’s team excluded this group from the analysis, the vaccine was 60% effective. Madhi says that he’d expected the vaccine to perform much worse against 501Y.V2 than against other variants. That’s because emerg- ing data had shown that the variant was imper- vious to many of the potent ‘neutralizing’, or virus-blocking, antibodies generated by people who had received other vaccines or had recovered from infection. “A vaccine efficacy of 60% is something which I certainly didn’t dream of when I started to see all of the other PA IMAGES/ALAMY PA data that was coming out.” Novavax’s protein-based vaccine relies on tried-and-tested technology. The South African trial was not large enough to determine whether the vaccine is better at preventing severe cases of COVID-19 than it is at preventing milder infections. But evidence NOVAVAX COVID VACCINE that other COVID-19 vaccines work in this way suggests that the Novavax jab will do, too, says PROTECTS PEOPLE Madhi. “I believe this vaccine will impact on hospitalization and severe disease, probably AGAINST VARIANTS north of 60%.” Trial data also suggested that people who But the experimental shot saw a worrying drop in had previously been infected with the original lineage were not protected against re- infection efficacy against a lineage detected in South Africa.
    [Show full text]
  • Vacinas Baseadas Em Vírus Inativado Para Prevenção Da Covid-19
    MINISTÉRIO DA ECONOMIA INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL OBSERVATÓRIO DE TECNOLOGIAS RELACIOADAS À COVID-19 VACINAS BASEADAS EM VÍRUS INATIVADO PARA PREVENÇÃO DA COVID-19 Autora: Tatiana Carestiato da Silva Colaboradoras: Cristina d’Urso de Souza Mendes Irene von der Weid Leticia Galeazzi Ferraz Núbia Gabriela Benício Chedid Nota de Copyright: Autorizada a reprodução desde que seja citada a fonte Equipe Observatório COVID-19 Alexandre Lopes Lourenço Cristina d’Urso de Souza Mendes Irene von der Weid Leticia Galeazzi Ferraz Núbia Gabriela Benício Chedid Tatiana Carestiato VACINAS BASEADAS EM VÍRUS INATIVADO Ademais, a invasão viral induz dano nas células, PARA PREVENÇÃO DA COVID-19 piroptose, infiltração de células imunes, expressão de citocinas pró-inflamatórias (tempestade de citocinas) e ativação do sistema imune adaptativo. Dependendo da carga viral e de 1. INTRODUÇÃO fatores do hospedeiro, como idade e condições médicas subjacentes, as respostas imunes contra o SARS-CoV-2 podem causar síndrome do desconforto respiratório agudo (SDRA), A COVID-19 é uma doença respiratória infecciosa falência de múltiplos órgãos e até a morte (Figura 2) (Chugh, et causada pelo SARS-CoV-2 (Figura 1) um novo beta al., 2021). coronavírus. Sendo principalmente uma doença respiratória, Os primeiros quadros respiratórios provocados pela ela é altamente transmissível por contatos diretos e indiretos e COVID-19 foram reportados às autoridades internacionais em exibe uma variedade de sintomas em diferentes indivíduos 31 de dezembro de 2019. Em janeiro de 2020, menos de um (Chugh, et al., 2021). mês depois que surgiram os primeiros relatórios da doença respiratória que estava atingindo as pessoas na cidade chinesa de Wuhan, os pesquisadores do país identificaram a causa: um novo coronavírus, que logo se chamaria SARS-CoV-2.
    [Show full text]
  • Shabir a Madhi Professor Shabir Madhi Date of Birth: 28 November 1966 Nationality: South African
    CURRICULUM VITAE : Shabir A Madhi Professor Shabir Madhi Date of Birth: 28 November 1966 Nationality: South African 1. Most Recent Current and Past Work Positions: i). Executive Director: National Institute for Communicable Diseases, National Health Laboratory Service. (2011-Current) ii). Professor of Vaccinology; School of Pathology; Univ. of Witwatersrand (2008-current) iii). Chair: Department of Science and Technology/ National Research Foundation – Vaccine Preventable Diseases. (2008 -current) iv). Co-director: University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit. (2007 -2013) v). Director: University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit. (2007 -2013) vi). Honorary Consultant: Department of Paediatrics. (1997 -2005) 2. PROFESSIONAL QUALIFICATIONS 1990: Bachelor of Medicine and Bachelor of Surgery (MBBCh); University of the Witwatersrand, Johannesburg 1996: Fellow College of Paediatrics (FCPaeds (SA); College of Medicine of South Africa 1998: Masters in Medicine (MMed Paediatrics); University of the Witwatersrand, Johannesburg 2001-2010: Sub-speciality registration - Critical Care Paediatrics. Health Professional Council of South Africa 2003: PhD (Health Sciences); University of the Witwatersrand, Johannesburg. 2010: Sub-speciality registration – Infectious Diseases. Health Professional Council of South Africa 3. MEMBERSHIP OF PROFESSIONAL BODIES/ASSOCIATIONS i). Member: South African Medical Association (1996-) ii). Fellow: College of South Africa (1997-) iii). Member: South African Paediatric Association (1997-) iv). Member: Critical Care Society of South Africa. (2002-2009) v). Member: Federation of Infectious Diseases Society of South Africa. (2002-) vi). Member: European Society of Paediatric Infectious Diseases (2003-) vii). Deputy-president: Southern African Society of Infectious Diseases (2008-2013) viii). Board member : International Scientific Committee – World Society of Paediatric Infectious Diseases (2008-2013) ix).
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 7 Giugno 2021
    Coronavirus: quello che c’è da sapere – 7 giugno 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Qual è l’origine del virus? .........................................................................4 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................46 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]